Oncolytics Biotech Inc. (ONCY)

NASDAQ: ONCY · IEX Real-Time Price · USD
1.01
-0.01 (-1.23%)
Jun 24, 2022 4:00 PM EDT - Market closed
-1.23%
Market Cap 58.37M
Revenue (ttm) n/a
Net Income (ttm) -26.65M
Shares Out 57.79M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 31,423
Open 1.03
Previous Close 1.02
Day's Range 1.00 - 1.03
52-Week Range 0.80 - 2.92
Beta 1.71
Analysts Buy
Price Target 5.68 (+462.4%)
Earnings Date Aug 5, 2022

About ONCY

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/... [Read more...]

Industry Biotechnology
IPO Date Nov 8, 1999
Employees 26
Stock Exchange NASDAQ
Ticker Symbol ONCY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ONCY stock is "Buy." The 12-month stock price forecast is 5.68, which is an increase of 462.38% from the latest price.

Price Target
$5.68
(462.38% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Pa...

Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB , June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. ...

Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference

SAN DIEGO, Calif. and CALGARY, AB , May 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will part...

Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights

Anticipated Q4 2022 data readout from randomized phase 2 study in breast cancer is on track and expected to inform the design of a registrational trial Clinical biomarker data demonstrates pelareorep's ...

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the...

Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study Statistically significant increas...

Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Brea...

SAN DIEGO, Calif. and CALGARY, AB , May 2, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract for ...

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Thursday, May 5, 2022, at 5:00 p.m. ET SAN DIEGO and CALGARY, AB , April 28, 2022 /PRNewswire/ --Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today ann...

Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference

SAN DIEGO, Calif. and CALGARY, AB , April 21, 2022 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will b...

Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of P...

- Pelareorep-CAR T combination may expand the commercial potential of CAR T cells to solid tumors - Combining CAR T cells with pelareorep prevented antigen escape by creating CAR T cells with dual speci...

Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual Conference

SAN DIEGO, Calif. and CALGARY, AB, April 12, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Thomas Heineman, M.D.

Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AAC...

- Results demonstrate meaningful and durable efficacy signal in a highly challenging indication - A higher dose level of pelareorep led to 50% 24-month median overall survival (mOS) and a patient still ...

Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma ...

- Pelareorep's immunotherapeutic effects produced progression-free survival of >3 years in a subset of multiple myeloma patients who had failed prior therapy - Results strengthen the clinical dataset de...

Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress

SAN DIEGO, Calif. and CALGARY, AB, April 6, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Mult...

Independent review identified, no safety concerns in trial's final safety run-in Cohort supported by prior clinical data showing a pelareorep-based combination driving a 90% clinical benefit rate in KRA...

Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatme...

First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date Trial is designed to satisfy regulatory requirements and accelerate pe...

Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of N...

SAN DIEGO and CALGARY, AB, March 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-rev...

Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibit...

- Prolonged progression-free survival of >3 years achieved in a subset of relapsed/refractory patients - Treatment-induced increases in tumor-infiltrating anti-cancer immune cells correlated with clinic...

Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting

SAN DIEGO, Calif. and CALGARY, AB, March 9, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced an upcoming poster presentation that will feature long-term follow-up ...

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Randomized phase 2 metastatic breast cancer trial (BRACELET-1) on track for top-line data in Q4 2022 Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a ...

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Oper...

SAN DIEGO, Calif.  and CALGARY, AB, Feb. 22, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, March 3,...

Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2...

Independent safety review completed with no toxicity concerns Cohort builds on prior proof-of-concept data demonstrating clinical benefit of pelareorep-checkpoint inhibitor combination in pancreatic can...

Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial ...

Enrollment in the first dose escalation is complete with no safety issues reported to date Trial is designed to accelerate pelareorep's development in Asian territories such as China, the world's second...

Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 202...

SAN DIEGO, Calif. and CALGARY, Canada, Jan. 20, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentati...

4 Penny Stocks To Buy For Under $4 Right Now

Cheap penny stocks to watch right now. The post 4 Penny Stocks To Buy For Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: ADMADARERETO

Oncolytics Biotech® Releases a Letter to Shareholders - 2021 Review and 2022 Outlook

SAN DIEGO, Calif. and CALGARY, AB, Jan. 11, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.

Oncolytics Biotech® Promotes Thomas C. Heineman, M.D.

- Dr. Heineman has over two decades of experience successfully leading clinical development programs and previously served as Oncolytics' Global Head of Clinical Development and Operations SAN DIEGO and...